Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Dec 11

PMID 33302406

Citations 16

Authors

Elzbieta Poreba

Krzysztof Lesniewicz

Julia Durzynska

Affiliations

Soon will be listed here.

Abstract

KMT2 (histone-lysine N-methyltransferase subclass 2) complexes methylate lysine 4 on the histone H3 tail at gene promoters and gene enhancers and, thus, control the process of gene transcription. These complexes not only play an essential role in normal development but have also been described as involved in the aberrant growth of tissues. KMT2 mutations resulting from the rearrangements of the KMT2A (MLL1) gene at 11q23 are associated with pediatric mixed-lineage leukemias, and recent studies demonstrate that KMT2 genes are frequently mutated in many types of human cancers. Moreover, other components of the KMT2 complexes have been reported to contribute to oncogenesis. This review summarizes the recent advances in our knowledge of the role of KMT2 complexes in cell transformation. In addition, it discusses the therapeutic targeting of different components of the KMT2 complexes.

Citing Articles

KMT2A facilitates the epithelial-to-mesenchymal transition and the progression of ovarian cancer.

Zhu Y, Jiang S, Tang R, Chen H, Jia G, Zhou X Mol Cell Biochem. 2024; .

PMID: 39589456 DOI: 10.1007/s11010-024-05167-x.

Uncovering a Genetic Diagnosis in a Pediatric Patient by Whole Exome Sequencing: A Modeling Investigation in Wiedemann-Steiner Syndrome.

di Bari I, Ceccarini C, Curcetti M, Cesarano C, Croce A, Adipietro I Genes (Basel). 2024; 15(9).

PMID: 39336746 PMC: 11431573. DOI: 10.3390/genes15091155.

The Ubiquitin-Conjugating Enzyme E2 O (UBE2O) and Its Therapeutic Potential in Human Leukemias and Solid Tumors.

Maffeo B, Cilloni D Cancers (Basel). 2024; 16(17).

PMID: 39272922 PMC: 11394522. DOI: 10.3390/cancers16173064.

KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis.

Sigafoos A, Tolosa E, Carr R, Fernandez-Barrena M, Almada L, Pease D Cancer Res Commun. 2024; 4(7):1677-1689.

PMID: 38896052 PMC: 11232480. DOI: 10.1158/2767-9764.CRC-23-0464.

Roles and Regulation of H3K4 Methylation During Mammalian Early Embryogenesis and Embryonic Stem Cell Differentiation.

Terzi Cizmecioglu N Adv Exp Med Biol. 2024; 1470:73-96.

PMID: 38231346 DOI: 10.1007/5584_2023_794.

References

Yang Z, Augustin J, Hu J, Jiang H . Physical Interactions and Functional Coordination between the Core Subunits of Set1/Mll Complexes and the Reprogramming Factors. PLoS One. 2015; 10(12):e0145336. PMC: 4686221. DOI: 10.1371/journal.pone.0145336. View

Southall S, Wong P, Odho Z, Roe S, Wilson J . Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell. 2009; 33(2):181-91. DOI: 10.1016/j.molcel.2008.12.029. View

Kim J, Banerjee T, Vinckevicius A, Luo Q, Parker J, Baker M . A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer. Mol Cell. 2014; 54(4):613-25. PMC: 4075454. DOI: 10.1016/j.molcel.2014.03.043. View

Couture J, Skiniotis G . Assembling a COMPASS. Epigenetics. 2013; 8(4):349-54. PMC: 3674043. DOI: 10.4161/epi.24177. View

Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield V . hDOT1L links histone methylation to leukemogenesis. Cell. 2005; 121(2):167-78. DOI: 10.1016/j.cell.2005.02.020. View

Schindler U, Beckmann H, Cashmore A . HAT3.1, a novel Arabidopsis homeodomain protein containing a conserved cysteine-rich region. Plant J. 1993; 4(1):137-50. DOI: 10.1046/j.1365-313x.1993.04010137.x. View

Liu L, Kimball S, Liu H, Holowatyj A, Yang Z . Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget. 2014; 6(4):2466-82. PMC: 4385864. DOI: 10.18632/oncotarget.2967. View

Kim S, Lee M, Lee M . Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat. 2020; 180(1):45-54. PMC: 7031178. DOI: 10.1007/s10549-019-05517-0. View

Kaikkonen M, Spann N, Heinz S, Romanoski C, Allison K, Stender J . Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol Cell. 2013; 51(3):310-25. PMC: 3779836. DOI: 10.1016/j.molcel.2013.07.010. View

10.

Super H, McCabe N, Thirman M, Larson R, Le Beau M, Pedersen-Bjergaard J . Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993; 82(12):3705-11. View

11.

Salz T, Deng C, Pampo C, Siemann D, Qiu Y, Brown K . Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in Breast Cancer. Mol Cancer Res. 2014; 13(3):461-9. DOI: 10.1158/1541-7786.MCR-14-0389. View

12.

Choi Y, Oh H, Choi M, Gwak M, An C, Chung Y . Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. Hum Pathol. 2014; 45(8):1674-81. DOI: 10.1016/j.humpath.2014.04.013. View

13.

Bueno C, Velasco-Hernandez T, Gutierrez-Aguera F, Zanetti S, Baroni M, Sanchez-Martinez D . CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. Leukemia. 2019; 33(8):2090-2125. PMC: 6756031. DOI: 10.1038/s41375-019-0418-8. View

14.

Krivtsov A, Armstrong S . MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007; 7(11):823-33. DOI: 10.1038/nrc2253. View

15.

Zhu J, Sammons M, Donahue G, Dou Z, Vedadi M, Getlik M . Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015; 525(7568):206-11. PMC: 4568559. DOI: 10.1038/nature15251. View

16.

Tamkun J, Deuring R, Scott M, Kissinger M, Pattatucci A, Kaufman T . brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell. 1992; 68(3):561-72. DOI: 10.1016/0092-8674(92)90191-e. View

17.

Guenther M, Lawton L, Rozovskaia T, Frampton G, Levine S, L Volkert T . Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2009; 22(24):3403-8. PMC: 2607073. DOI: 10.1101/gad.1741408. View

18.

Ruthenburg A, Allis C, Wysocka J . Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell. 2007; 25(1):15-30. DOI: 10.1016/j.molcel.2006.12.014. View

19.

Bulger M, Groudine M . Functional and mechanistic diversity of distal transcription enhancers. Cell. 2011; 144(3):327-39. PMC: 3742076. DOI: 10.1016/j.cell.2011.01.024. View

20.

Zhang L, Zhang S, Li A, Zhang A, Zhang S, Chen L . DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells. Int J Mol Med. 2018; 42(6):3065-3072. PMC: 6202113. DOI: 10.3892/ijmm.2018.3869. View